Track the evolution of major financial and economic events
On May 28, The Clorox Company announced that Chair and CEO Linda Rendle has decided to step down for health reasons. The Board of Directors has initiated a comprehensive search process to appoint a new CEO.
American Eagle beats revenue estimates thanks to the strength of the Aerie brand, offsetting a decline in its core brand. However, American Eagle's stock plummeted 10% due to weak outlook and a slowdown in the retail sector. In Q1, American Eagle surpassed estimates as revenue climbed 9.7%.
Costco's same-store sales surged 9.8% in Q3, boosted by gasoline sales. Despite missing earnings per share targets, Costco's revenue topped $70 billion in Q3, reflecting consumer spending resilience.
Amazon announced plans to bolster its AWS cloud services by integrating xAI's Grok models. The company also intends to invest $20 billion in the UK in 2025 to expand its infrastructure. Additionally, Amazon launched Prime in South Africa to fuel its expansion in the African continent.
On May 28, Snowflake shares experienced a record surge following a $6 billion deal with Amazon. The software maker also provided a strong financial outlook for its future performance. On May 29, Snowflake's shares jumped 36% after reporting strong earnings and upbeat AI-driven guidance.
Coinbase announced its partnership with Standard Chartered to expand its global fiat services for institutions. Coinbase also opened crypto derivatives trading to US institutional clients via Deribit. Additionally, Coinbase partnered with Checkout.com to enable stablecoin payments for over 1,000 brands. Finally, Coinbase will list Ethena's USDe stablecoin, resulting in a 28% surge in the price of the ENA token.
Innio Group is targeting a valuation of up to $20.3 billion for its upcoming U.S. IPO. The company plans to offer 75 million shares priced between $24 and $27 each. It is backed by Advent International and the Abu Dhabi Investment Authority and was formerly a carve-out from General Electric.
US stocks experienced a post-earnings drift, with Seagate shares surging 35%. In contrast, Starbucks and Visa stocks lagged behind, failing to achieve similar performance.
On May 28, xAI signed a major deal with Anthropic for the exclusive use of its Colossus compute cluster. The deal is worth billions of dollars per month.
NVIDIA has pledged a $150 billion investment in Taiwan to strengthen the AI supply chain. The company also unveiled the Vera CPU optimized for AI agents. Additionally, IREN secured a $3.65 billion loan for NVIDIA GPUs to power Microsoft's AI infrastructure. ASUS has adopted NVIDIA's DSX AI Factory to scale AI infrastructure solutions.
On May 28, Tyson Foods announced the appointment of board member Jeff Schomburger as its new president and chief executive officer. Schomburger will succeed Donnie King in leading the meat processing company.
On May 28, Zayo Group completed its largest acquisition to date by purchasing Crown Castle's fiber assets. This deal aims to enhance the infrastructure for artificial intelligence, reflecting Zayo's commitment to expanding its capabilities in this area.
On May 28, Veracyte reported a 21% revenue growth in its Q1 2026 results. Non-GAAP gross margins expanded to 76%. Following strong cash generation, the company raised its 2026 guidance.
On May 28, eDreams ODIGEO reported a record adjusted net income of €72.9 million, representing a 42% increase. These results exceeded the FY2026 guidance.
Boston Scientific shares fell by 12.53% on May 27 after the company reiterated its lackluster full-year organic growth guidance. This decline reflects investor concerns about the company's future performance.
On May 27, the Pentagon announced a five-year agreement worth $9.69 billion to consolidate software licenses across military services. Dell won the contract after a competitive process to provide a suite of software to the U.S. Department of Defense. Dell shares rose 3% in premarket trading after the contract was awarded, and the company's market value has more than doubled this year.
Major Canadian banks, including BMO, Scotiabank, and National Bank of Canada, surpassed analyst profit expectations for the second quarter ending April 30. BMO reported a significant 34% year-over-year increase in net income to $2.63 billion. All three banks announced an increase in their quarterly dividend payments.
F5 shares have surged 56% this year, driven by strong institutional buying interest. On May 27, the company reported an 11% year-over-year revenue increase for the second fiscal quarter of 2026.
Gorilla Technology saw a 55% increase in Q1 revenue, reaching $28.2 million, with positive operating cash flow of $6.6 million. The company also raised its full-year 2026 revenue guidance to between $160 million and $200 million. On June 3, Gorilla closed a $2 billion AI infrastructure deal in India with Supermicro, which includes the delivery of cards and networking equipment to support the Yotta AI project.
Skyline Champion reported quarterly earnings of $0.68 per share, beating the consensus estimate of $0.63. The company's revenue reached $621.28 million, marking a 4.6% increase from the prior-year period. The company sold a record 26,622 homes during its fiscal year amid high traditional housing prices.
Insulet Corporation recalled approximately 7 million Omnipod insulin pump pods due to a manufacturing defect causing insulin leakage. This recall was announced on May 26, raising concerns among users about the safety of the product.
Cameco's adjusted EBITDA surged 44% to CAD 509 million in Q1 2026, driven by strength in the uranium segment. On May 27, nuclear power startup Newcleo announced its plans to go public through a SPAC deal, valuing the developer at approximately $2.4 billion.
On May 26, BP's board of directors removed Chairman Albert Manifold with immediate effect following a unanimous vote. BP's London-listed shares fell by 9% after the news of the chairman's removal. The removal was triggered by issues related to governance standards, oversight, and conduct raised with the board.
The U.S. FDA granted Outlook Therapeutics' appeal for the retinal drug LYTENAVA following a Formal Dispute Resolution process. The company plans to resubmit its biologics license application in June 2026. If approved, LYTENAVA would be the first FDA-approved ophthalmic formulation of bevacizumab with FDA-approved manufacturing and labeling.
